Shionogi & Co Рыночная капитализация
Что обозначает Рыночная капитализация в Shionogi & Co?
Рыночная капитализация Shionogi & Co., Ltd. является $14.92B
Какое определение для Рыночная капитализация?
Рыночная капитализация - это рыночная стоимость в тот момент времени, когда акции, находящиеся в обращении публичной компании, равна цене акций в тот отрезок времени, умноженной на количество акций в обращении .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Рыночная капитализация компаний в Health Care сектор на OTC по сравнению с Shionogi & Co
Что делает Shionogi & Co?
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Компании с рыночная капитализация похож на Shionogi & Co
- Ryanair Plc имеет Рыночная капитализация из $14.80B
- Symantec имеет Рыночная капитализация из $14.81B
- Associated British Foods Plc имеет Рыночная капитализация из $14.82B
- PT Astra International Tbk имеет Рыночная капитализация из $14.82B
- Guangzhou Automobile Co имеет Рыночная капитализация из $14.86B
- Shimano имеет Рыночная капитализация из $14.88B
- Shionogi & Co имеет Рыночная капитализация из $14.92B
- Swedbank AB (publ) имеет Рыночная капитализация из $14.92B
- Avantor имеет Рыночная капитализация из $14.93B
- Grasim Industries имеет Рыночная капитализация из $14.93B
- Sonova AG имеет Рыночная капитализация из $14.94B
- HDFC Life Insurance имеет Рыночная капитализация из $14.96B
- Symrise AG имеет Рыночная капитализация из $14.96B